M
Min Gao
Researcher at Bristol-Myers Squibb
Publications - 78
Citations - 5614
Min Gao is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Hepatitis C virus & NS5A. The author has an hindex of 35, co-authored 73 publications receiving 5312 citations.
Papers
More filters
Journal ArticleDOI
RNA template-mediated inhibition of hepatitis C virus RNA-dependent RNA polymerase activity.
TL;DR: Inhibition of NS5B activity by RNA template exhibited characteristics of substrate inhibition, suggesting the template binds to a secondary site on the enzyme forming an inactive complex, and template inhibition was modulated by primer.
Journal ArticleDOI
METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism.
Lijuan Han,Lei Dong,Keith Chin-Kee Leung,Zhi-Ning Zhao,Yangchan Li,Lei Gao,Zhenhua Chen,Jingling Xue,Ying Qing,Wei Li,Sheela Pangeni Pokharel,Min Gao,Meiling Chen,Chao Shen,Brandon Tan,Andrew M. Small,Kitty Wan Ching Wang,Zheng-Zhong Zhang,Xi Qin,Lucie Yang,Mark Wunderlich,Bin Amber Zhang,James C. Mulloy,Guido Marcucci,Chun-Wei Chen,Minjie Wei,Rui Su,Jianjun Chen,Xiaolan Deng +28 more
TL;DR: In this article , the authors show that METTL16 is a highly essential gene for the survival of acute myeloid leukemia (AML) cells via CRISPR-Cas9 screening and experimental validation.
Journal ArticleDOI
Investigation of the mode of binding of a novel series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamides to the hepatitis C virus polymerase.
Robert G. Gentles,Steven Sheriff,Brett R. Beno,Changhong Wan,Kevin Kish,Min Ding,Xiaofan Zheng,Louis S. Chupak,Michael A. Poss,Mark R. Witmer,Paul E. Morin,Ying-Kai Wang,Karen Rigat,Julie A. Lemm,Voss Stacey A,Mengping Liu,Lenore A. Pelosi,Susan B. Roberts,Min Gao,John F. Kadow +19 more
TL;DR: Comparison of co-crystal structures of a potent analog with both NS5B genotypes 1a and genotype 1b provides a possible explanation for the genotype-selectivity observed with this compound class and suggests opportunities for the further optimization of the series.
Patent
Hepatitis C virus assays
TL;DR: In this article, the authors presented a dual HCV assay useful for high-throughput screening that quantifies both the amount of HCV RNA replication inhibitory activity associated with a test compound and its cytotoxicity associated with that test compound.
Journal ArticleDOI
Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis.
Susheel J. Nara,Srinivas Jogi,Srinivasa Rao Cheruku,Sarkunam Kandhasamy,Firoz A. Jaipuri,Pavan Kalyan Kathi,Subba Reddy,Sanket Sarodaya,Erica Cook,Tao Farmington Wang,Doree F. Sitkoff,Karen A. Rossi,Max Ruzanov,Susan E. Kiefer,Javed Khan,Min Gao,Satyanarayana Reddy,Sankara Sivaprasad Lvj,Ramola Vishwas Sane,Kathleen W. Mosure,Xiaoliang Zhuo,Gary Cao,Milinda Ziegler,Antonio Azzara,John Krupinski,Matthew G. Soars,Bruce A. Ellsworth,Dean A. Wacker +27 more
TL;DR: This is the first report that demonstrates differential induction of Fgf15 in the liver and ileum by FXR agonists in vivo, suggesting that the additional pharmacology of BMS-986318 does not further benefit efficacy, possibly presenting an opportunity for reduced adverse effects.